Form 4: Seres Therapeutics Director, Stephen Berenson, Acquires Stock Options

Director Stephen Berenson acquired stock options in Seres Therapeutics, Inc. on July 1, 2024.

Summary

• Stephen Berenson, a director of Seres Therapeutics, Inc., acquired stock options on July 1, 2024.
• The stock options grant the right to buy 114,782 shares of common stock at an exercise price of $0.72.
• The options vest in four equal quarterly installments starting October 1, 2024, and ending July 1, 2025 (or earlier if the 2025 annual meeting occurs before July 1, 2025).
• The options expire on June 30, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding more than 10% of a company's shares) trade in their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• The acquisition of stock options by a director may signal confidence to shareholders.

Key Dates